Page 32 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

GECU donates $50,000 to UMC for cancer care

The GECU Foundation donated $50,000 to the University Medical Center Foundation for cancer support services. In recognition of the gift, a nurse’s station at University Medical Center of El Paso ....

El Paso , University Medical Center , Foundation People , University Medical Center Foundation , People Helping , Sobreviviendo El Cancer , Ob Market ,

2 Minute Medicine Rewind January 8, 2023 | 2 Minute Medicine

Effect of probiotic supplementation on lipoprotein-associated phospholipase A2 in type 2 diabetic patients: a randomized double-blind clinical controlled trial 1. Patients with type 2 diabetes randomized to using probiotic supplements were found to have significantly reduced lipoprotein-associated phospholipase A2 levels at 12-weeks follow-up. 2. Probiotic supplementation was also associated with improved glycemic control at follow-up. ....

North Carolina , United States , Level Rating , Bacillus Coagulans , Safe Passage Study , Prenatal Alcohol , End Of Life Screening Tool , Covid 19 , Critical Care , Palliative Care , Public Health , Weekly Rewinds ,

Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive Breast Cancer or Lung Cancer

1. Progression-free survival in NSCLC was found to be significant with HR 0.41 compared to breast cancer which was non-significant with HR 0.78. 2. Grade 2 or worse adverse events occurred 41% in the standard-of-care group vs 62% in the SBRT group. Evidence Rating Level: 1 (Excellent) Study Rundown: The treatment paradigm for metastatic cancer ....

Rating Level , Comprehensive Treatment , Oligometastatic Cancers , Long Term Results , Oligometastatic Cancer , Radiation Therapy , Stereotactic Body Radiotherapy , Chronic Disease ,

Comparison of two chemotherapy regimens in muscle invasive bladder cancer

1. In the perioperative setting, there was no difference between dd-MVAC vs. GC on overall 5-year survival. 2. In the neoadjuvant subgroup, findings from the VESPER trial revealed a notable improvement in 5-year overall survival and time to death from bladder cancer among individuals treated with dd-MVP compared to those receiving the GC regimen. Evidence ....

Rating Level , Dd Mvac , Muscle Invasive Bladder Cancer , Urothelial Cancer , Chronic Disease ,

Perioperative pembrolizumab with chemotherapy for gastric and gastroesophageal junction adenocarcinoma improves pathological complete response rate compared with placebo

1. The median overall survival and event-free survival were not statistically different in the pembrolizumab group as compared to the placebo group. 2. The frequency of serious adverse events (AEs) of grade 3 or worse was comparable between experimental and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: While the gold standard treatment for ....

Minute Medicine Inc , Rating Level , Practice Guideline , Gastric Cancer , Gej Adenocarcinoma , Chronic Disease ,